Spero Therapeutics, Inc., a leading biopharmaceutical company based in Cambridge, Massachusetts, is committed to developing innovative treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company will provide an update on their first quarter 2024 financial results and share details about their pipeline on May 15th, after the market closes. Unfortunately, they have decided not to host a conference call for this announcement but plan to resume quarterly earnings calls when the second quarter 2024 results are released.
Spero Therapeutics is at the forefront of developing novel treatments for rare diseases and MDR bacterial infections. Their lead product candidate, SPR720, is an oral first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD) and is currently being studied in a Phase 2A proof of concept trial. NTM-PD is a rare lung disease caused by non-tuberculous mycobacterial infections.
In addition to SPR720, Spero Therapeutics is also developing Tebipenem HBr, an oral drug that is currently in a Phase 3 registrational trial for the treatment of complicated urinary tract infections, including pyelonephritis. Spero has granted GSK an exclusive license to commercialize tebipenem HBr in most territories, excluding certain Asian territories.
Another innovation from Spero Therapeutics is SPR206, an investigational IV-administered direct-acting next-generation polymyxin that demonstrates antibiotic activity against MDR Gram-negative pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The FDA has cleared an IND application to advance SPR206 into a Phase 2 clinical trial for participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information about Spero Therapeutics and their groundbreaking work, you can visit their website at